摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3R)-6-cyclohexyl-3-[3-(2-pyrazinyl)-1,2,4-oxadiazol-5-yl]hexanoic acid | 468068-63-5

中文名称
——
中文别名
——
英文名称
(3R)-6-cyclohexyl-3-[3-(2-pyrazinyl)-1,2,4-oxadiazol-5-yl]hexanoic acid
英文别名
(3R)-6-cyclohexyl-3-(3-pyrazin-2-yl-1,2,4-oxadiazol-5-yl)hexanoic acid
(3R)-6-cyclohexyl-3-[3-(2-pyrazinyl)-1,2,4-oxadiazol-5-yl]hexanoic acid化学式
CAS
468068-63-5
化学式
C18H24N4O3
mdl
——
分子量
344.414
InChiKey
AJWCDPUNHNOQRX-CQSZACIVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    25
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.61
  • 拓扑面积:
    102
  • 氢给体数:
    1
  • 氢受体数:
    7

反应信息

  • 作为反应物:
    描述:
    (3R)-6-cyclohexyl-3-[3-(2-pyrazinyl)-1,2,4-oxadiazol-5-yl]hexanoic acid三乙胺氯甲酸异丁酯O-(三甲基硅)羟胺甲醇 作用下, 以 四氢呋喃 为溶剂, 反应 2.5h, 以0.76 g的产率得到(3R)-6-cyclohexyl-N-hydroxy-3-[3-(2-pyrazinyl)-1,2,4-oxadiazol-5-yl]hexanamide
    参考文献:
    名称:
    Potent and Selective Nonpeptidic Inhibitors of Procollagen C-Proteinase
    摘要:
    6-Cyclohexyl-N-hydroxy-3-(1,2,4-oxadiazol-5-yl)hexanamides were previously disclosed as inhibitors of procollagen C-proteinase (PCP) culminating in the identification of amide 1. Our objective was to discover a second inhibitor that would have improved affinity for PCP and to optimize properties for transepidermal delivery (TED) to intact skin. Further investigation of this template identified a number of potent PCP inhibitors (IC50 values of 2-6 nM) with improved TED flux. Sulfonamide 56 had excellent PCP enzyme activity when measured with a peptide substrate (K-i 8.7 nM) or with the endogenous substrate procollagen (IC50 3.4 nM) and demonstrates excellent selectivity over MMPs involved in wound healing (> 10 000-fold). In the fibroplasia model, 56 inhibited deposition of insoluble collagen by 76 +/- 2% at 10 mu M and was very effective at penetrating human skin in vitro with a TED flux of 1.5 mu g/cm(2)/h, which compares favorably with values for agents that are known to penetrate skin well in vivo. Based on this profile, 56 (UK-421,045) was selected as a candidate for further preclinical evaluation as a topically applied, dermal anti-scarring agent.
    DOI:
    10.1021/jm061010z
  • 作为产物:
    描述:
    tert-butyl (3R)-6-cyclohexyl-3-[3-(2-pyrazinyl)-1,2,4-oxadiazol-5-yl]hexanoate三氟乙酸 作用下, 以 二氯甲烷 为溶剂, 反应 2.0h, 以0.56 g的产率得到(3R)-6-cyclohexyl-3-[3-(2-pyrazinyl)-1,2,4-oxadiazol-5-yl]hexanoic acid
    参考文献:
    名称:
    Potent and Selective Nonpeptidic Inhibitors of Procollagen C-Proteinase
    摘要:
    6-Cyclohexyl-N-hydroxy-3-(1,2,4-oxadiazol-5-yl)hexanamides were previously disclosed as inhibitors of procollagen C-proteinase (PCP) culminating in the identification of amide 1. Our objective was to discover a second inhibitor that would have improved affinity for PCP and to optimize properties for transepidermal delivery (TED) to intact skin. Further investigation of this template identified a number of potent PCP inhibitors (IC50 values of 2-6 nM) with improved TED flux. Sulfonamide 56 had excellent PCP enzyme activity when measured with a peptide substrate (K-i 8.7 nM) or with the endogenous substrate procollagen (IC50 3.4 nM) and demonstrates excellent selectivity over MMPs involved in wound healing (> 10 000-fold). In the fibroplasia model, 56 inhibited deposition of insoluble collagen by 76 +/- 2% at 10 mu M and was very effective at penetrating human skin in vitro with a TED flux of 1.5 mu g/cm(2)/h, which compares favorably with values for agents that are known to penetrate skin well in vivo. Based on this profile, 56 (UK-421,045) was selected as a candidate for further preclinical evaluation as a topically applied, dermal anti-scarring agent.
    DOI:
    10.1021/jm061010z
点击查看最新优质反应信息

文献信息

  • 3-heterocyclylpropanohydroxamic acid PCP inhibitors
    申请人:——
    公开号:US20030069291A1
    公开(公告)日:2003-04-10
    Compounds of formula (I): 1 and their salts, solvates, hydrates and prodrugs are useful PCP inhibitors, processes for making the same, compositions comprising the same, and methods of treating a PCP-mediated condition or disease using the same.
    式(I)的化合物及其盐、溶剂合物、合物和前药是有用的PCP抑制剂,制备这些化合物的方法,包含这些化合物的组合物,以及使用这些化合物治疗PCP介导的疾病或病症的方法。
  • 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS
    申请人:Pfizer Limited
    公开号:EP1373264A1
    公开(公告)日:2004-01-02
  • US6821972B2
    申请人:——
    公开号:US6821972B2
    公开(公告)日:2004-11-23
  • [EN] 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS<br/>[FR] ACIDE 3-HETEROCYCLYLPROPANOHYDROXAMIQUE EN TANT QU'INHIBITEUR DE PROCOLLAGENE C-PROTEINASE
    申请人:PFIZER LTD
    公开号:WO2002079200A1
    公开(公告)日:2002-10-10
    Compounds of compounds of formula (I) and their salts, solvates and prodrugs, wherein the substituents are as defined herein, are Procollagen C-proteinase inhibitors for the treatment of scars.
查看更多